{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-26-000053","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2026-08-13T20:07:54+00:00","discovered_at":"2026-08-13T20:10:02.663337+00:00","generated_at":"2026-08-13T20:10:10.664835+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caribou Q2 2026 net loss $24.3M; vispa-cel and CB-011 show strong efficacy data","bullets":["Q2 2026 net loss $24.3M ($0.24/share) vs $54.1M ($0.58) in Q2 2025, which included $21.3M impairment.","Revenue $1.5M vs $2.7M; R&D $18.9M vs $27.7M; G&A $7.9M vs $10.4M.","Cash $113.8M at June 30, 2026, expected to fund operations to end of 2027.","ANTLER data: 82% ORR, 67% CR, 17.1-month median PFS in 2L LBCL (N=27) for vispa-cel.","CB-011 CaMMouflage: 92% ORR, 83% ≥CR, 91% MRD negativity; initial dose expansion data expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-26-000053","json":"https://secwatch.observer/filing/0001619856-26-000053.json","markdown":"https://secwatch.observer/filing/0001619856-26-000053.md","text":"https://secwatch.observer/filing/0001619856-26-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/0001619856-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985626000053/crbu-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:10:10.664835+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}